September 16, 2016 08:29 AM EDTUpdated September 18, 06:47 PM
Deals

An ac­quis­i­tive Cel­gene looks ready to pop a new mul­ti­ple myelo­ma deal

John Carroll

Editor & Founder

Is Cel­gene $CELG about to un­veil a new deal BC­MA-tar­get­ing deal? A sharp-eyed Bri­an Abra­hams at Jef­feries spot­ted a no­tice post­ed at the FTC …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times